GSK Secures EU COPD Nod for Nucala and ShoreCap Sees £40 bn Revenue Pathway
The European Commission approved Nucala as a monthly add-on maintenance treatment for uncontrolled COPD in adults with elevated eosinophil counts, marking its first EU COPD indication after positive phase III MATINEE data. Separately, Shore Capital raised GSK’s valuation pathway, projecting £40 billion in 2031 revenues and a 2,500p share justification.
1. EU Approval Expands Nucala COPD Indication
GSK received European Commission approval for Nucala (mepolizumab) as an add-on maintenance therapy in adults with uncontrolled COPD and raised blood eosinophil counts using triple inhaled therapy, based on phase III MATINEE trial data showing significant reductions in moderate/severe exacerbations and hospitalizations.
2. Shore Capital Projects £40 billion Revenue Ambition
Shore Capital analysts assert GSK has effectively delivered its medium-term plan ahead of schedule and deem the company’s goal of £40 billion in revenues by 2031 achievable, supporting a 2,500p share price justification driven by Nucala growth, pipeline progress and cost efficiencies.